| Hans-Günter Meyer-Thompson | Hepatitiden
Cost-effectiveness of Direct-acting Antivirals for Treatment of Hepatitis C Genotypes 2–6
Cost-effectiveness of Direct-acting Antivirals for Treatment of Hepatitis C Genotypes 2–6
T. He; M. A. Lopez-Olivo; C. Hur; J. Chhatwal
Aliment Pharmacol Ther. 2017;46(8):711-721.